-$0.69 Earnings Per Share Expected for Acer Therapeutics Inc (ACER) This Quarter

Wall Street analysts predict that Acer Therapeutics Inc (NASDAQ:ACER) will report ($0.69) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Acer Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.66) and the lowest estimate coming in at ($0.72). Acer Therapeutics reported earnings per share of ($1.24) in the same quarter last year, which suggests a positive year-over-year growth rate of 44.4%. The company is expected to announce its next quarterly earnings report on Friday, May 11th.

According to Zacks, analysts expect that Acer Therapeutics will report full-year earnings of ($3.22) per share for the current year, with EPS estimates ranging from ($3.72) to ($2.83). For the next financial year, analysts expect that the company will post earnings of ($2.55) per share, with EPS estimates ranging from ($2.81) to ($2.07). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Acer Therapeutics.

How to Become a New Pot Stock Millionaire

Acer Therapeutics (NASDAQ:ACER) last released its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.10).

Several research firms have commented on ACER. Zacks Investment Research cut Acer Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, March 9th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Acer Therapeutics in a research note on Friday, March 9th. Roth Capital began coverage on Acer Therapeutics in a research note on Monday, February 26th. They issued a “buy” rating and a $70.00 target price on the stock. William Blair began coverage on Acer Therapeutics in a research note on Friday, February 16th. They issued an “outperform” rating on the stock. Finally, ValuEngine cut Acer Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Two analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $60.00.

ACER stock traded down $0.24 during midday trading on Thursday, reaching $19.25. The company’s stock had a trading volume of 9,141 shares, compared to its average volume of 31,638. The company has a market cap of $148.37, a PE ratio of -4.87 and a beta of 2.54. Acer Therapeutics has a 12-month low of $5.69 and a 12-month high of $22.63.

Large investors have recently bought and sold shares of the business. Ardsley Advisory Partners acquired a new position in shares of Acer Therapeutics during the 4th quarter worth approximately $212,000. Stonepine Capital Management LLC acquired a new position in shares of Acer Therapeutics during the 4th quarter worth approximately $1,385,000. J. Goldman & Co LP acquired a new position in shares of Acer Therapeutics during the 4th quarter worth approximately $1,496,000. Finally, Perceptive Advisors LLC acquired a new position in shares of Acer Therapeutics during the 4th quarter worth approximately $2,091,000. 7.41% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was published by Stock Observer and is the property of of Stock Observer. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.thestockobserver.com/2018/03/20/0-69-earnings-per-share-expected-for-acer-therapeutics-inc-acer-this-quarter.html.

About Acer Therapeutics

Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.

Get a free copy of the Zacks research report on Acer Therapeutics (ACER)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply